Frazis Capital Podcast

By Michael FrazisBusiness Investing

Frazis Capital Podcast episodes

November 29, 2021 Episode #56: Market review
Michael Frazis reviews the market.

1:35 – Fallen angels & Fed balance sheet taper 3:53 – Comments on Coupa 7:26 – Lightspeed 8:35 – Teladoc 13:15 – Twilio 14:40 – Roku 18:10 – Upstart 19:16 – EBR Systems 20:40 – PayPal and Visa 24:52 – Coupang 29:50 – Thoughts on inflation 31:46 – Question #1: Sea Limited 32:12 – Question #2: Comments on mid-cap growth companies that haven’t fallen 32:42 – Question #3: Portfolio outlook 36:22 – Question #4: Crypto for payments 38:07 – Question #5: Matterport 38:45 – Question #6: Additional question on Upstart 39:33 – Question #7: Comparison of current revenue multiples to early 2000’s 43:40 – Question #8: Update on Regeneron and the Biotech sector 47:51 – Question #9: PayPal vs. Square
50 min
November 17, 2021 Episode #55: Inflation strikes
1:00 – Thoughts on the recent inflation data from the US
3:06 – The 6% differential between the Fed funds rate and inflation, and its impact on the economy
4:31 – Parallels with inflation spikes in the seventies and nineties
7:36 – The effect of inflation on the Australian dollar
7:46 – The effect of inflation on companies – Cloudflare
9:00 – Comments on Lightspeed
9:43 – Comments on Cettire
10:27 – Comments on Upstart
15:35 – Thoughts on Opendoor’s recent results and Zillow’s exit
17:47 - Roblox’s continued explosive growth and its impact on the Metaverse
19:05 – Thoughts on MercadoLibre’s recent results
19:59 – Our number one pick in the crypto space – Galaxy Digital
21:07 – Two crypto coins that you can stake – Olympus and KlimaDAO
22:39 – Question #1: What is the impact of credit risk on companies like Upstart during economic downturns?
23:41- Question #2: Thoughts on Paypal?
24:28 – Question #3: Thoughts on DermTech’s recent quarterly?
25:37- Question #4 Thoughts on Marqeta?
25:55 – Question #5: Thoughts on Quantum-Si?
26:35 – Question #6: Have you ever owned Trade Desk?
27:22 - Question #7: What do you think of Fulgent Genetics?
28:30 – Question #8: Thoughts on Green Hydrogen?
30:14 – Question #9: Do you still hold and believe in TIGR/FUTU?
32:04 – Question #10: What’s the outlook on India for the next 5-10 years?
32:49 – Question #11: What platform do you use to purchase your crypto?
35 min
November 06, 2021 Episode 54: New venture fund, Web3, Zillow vs Opendoor, and questions answered
0:58 Launch of our Venture Fund
3:04 The benefits of pre-IPO access and our investment in Camplify
4:58 Private access to fast growing companies like Mawson Infrastructure
6:05 Zillow’s shrinking growth model
11:05 Comparative management decisions between Opendoor and Zillow
15:54 More on Zillow’s travails and management
17:29 The importance of customer love – Tesla
18:25 Tesla valuation thoughts
19:16 The NFT and crypto revolution
23:40 How crypto is transforming how games are played
27:48 Facebook’s lame Metaverse
29:53 The exciting prospects of games like Star Atlas
30:55 Our thoughts on Pinduoduo and Coupang
31:47 Chinese capital controls and its effects on FUTU and TIGR
33:44 What we like about Solana
34:24 The investment bank of the crypto world – Galaxy
35:50 Value in holding crypto companies – Voyager Digital
Q&A’s
36:30 Question: Would love to here your thoughts on FUTU?
37:03 Question: What’s the upside of Tesla’s valuation?
38:17 Question: Thoughts on great resignation and how work is changing?
39:40 Question: What are your thoughts on Zoom?
40:00 Question: Do you like Sandbox over MANA?
40:20 Question: Opening fund for retail?
40:28 Question: Thoughts on Paradigm Pharma?
42:00 Question: What are your thoughts on Chegg?
44:00 Question: What are your thoughts on Allbirds?
44:18 Question: Thoughts on inflation?
45:10 Question: Thoughts on Iris energy?
46:30 Question: CBA and crypto trading?
48:35 Question: What is the global gaming TAM and growth rate?
50:17 Criminal coins
53 min
September 23, 2021 Episode 53: How to build a deep tech company in aerospace from scratch, with Henry Bilinsky, founderCEO of MicroTau
Henry joins us to talk about his journey and experiences with surface science, engineering, and the US Airforce.
Timestamps
0:35 – How did MicroTau come to be?
2:08 – Henry discusses his involvement with InnoCentive challenges
5:16 – A challenge from the US Air Force Research Laboratory
6:26 – What is drag?
8:26 – How riblets found on shark skin can reduce drag
11:20 – Printing with light to create nano-scale features on surfaces
15:14 – Henry talks about his unexpected success with the US Air Force challenge
17:54 – Submitting a business proposal to the US Air Force
19:47 – The process of implementing the technology
22:13 – The carbon and cost savings associated with reducing friction drag on large-scale aircrafts
24:04 – The applications of MicroTau’s technology
27:18 – How the product will scale to large-scale surfaces
28:37 – MicroTau’s revenue model
30:35 – The process of approval in a highly-regulated industry
32:45 – MicroTau’s funding sources
33:30 – Support for start-ups in Australia
35:27 – What are some of the other applications for these riblets?
40:37 – Different types of surfaces and their applications
41:11 – Gecko pads
43:08 – Optical applications including visual adaptive camouflage
46:00 – Namib beetles
47:08 – What’s next for MicroTau?
48:48 – Growing the team
50:02 – MicroTau’s first active flight test this year
52 min
September 21, 2021 Episode 52: 20 September 2021 Update and Questions Answered
Michael Frazis gives an update and answers questions.

0:26 – Introduction
1:10 – Performance update
1:58 – Comments on the NASDAQ100’s strong rally
2:46 – The performance of small-mid cap companies
3:38 – An analyse of where our returns have come from over the years
4:20 – Our past investment in bluebird bio
5:39 – Our IPO/pre-IPO investments in the life sciences
6:57 – We funded a PhD fellowship on research into Dystonia
8:45 – True customer love and explosive growth
9:14 – Our take on ESG and the rising coal prices
10:40 – The effects of currency fluctuations on a fund’s performance
12:23 – Drivers in the value of the AUD
13:36 – Comments on Opendoor and the three industries that are resistant to ecommerce
16:25 – Comments on Upstart
18:42 – Thoughts on the decline in digital health companies
20:03 – Question #1: What do you think of PointsBet?
21:31 – Question #2: Do we still hold Guardent and Dermtech?
23:30 – Question #3: The contribution of the life science companies to the fund’s performance
26:08 – Question #4: Are you planning on taking advantage of the current dip in the market?
26:23 – Question #5: What are the risk management strategies when if the market turns?
28:51 – Question #6: Customer love in the life sciences
29:09 – Question #7: How has the recent move back into China-tech progressed?
30:12 – Question #8: What do you think of developer tools ecosystem DevOps?
30:51 – Question #9: What is an odd stock that looks good at the moment? (Camplify and Cettire)
31:35 – Question #10: What are your thoughts on Megaport?
31:50 – Question #11: What are your thoughts on cloud in general? (Snowflake)
32:58 – Question #12: Do you see the fund’s China positions as trading or long-term holds? (Pinduoduo)
36:25 – Question #13: Would eye-wear replace mobiles?
37:20 – Question #14: What are your thoughts on the recent Canva valuation?
40:18 – Question #15: What are your thoughts on Fiverr?
42 min
September 02, 2021 Episode 51: New antibodies, vaccines, and our portfolio companies Cettire, Futu, and Camplify report
Timestamps
0:15 Introduction to our strategy
2:55 How a company can lose money and still create value
4:38 Avoiding ‘deep value’ traps
5:30 Update on 2021 fund performance
6:50 How we’re investing in China
9:00 Update on FUTU’s Q2 results and why we bought more
12:18 Recently approved antibodies for COVID-19 – cause for optimism?
16:23 Update on Cettire’s FY21 results
18:03 How we evaluate business ‘quality’
19:00 Update on Camplify’s FY21 results
21:18 Question: thoughts on Digital Turbine
22:39 Question: thoughts on the recent Square and Afterpay deal
25 min
August 23, 2021 Episode 50: Reporting season and the next big thing in the life sciences
Michael Frazis gives an update
50 min
August 06, 2021 Episode 49: Regulatory crackdown in China and Square's acquisition of Afterpay
Michael Frazis gives an update.
29 min
July 19, 2021 Episode 48: SALT interview with Rachel Pether - true love and explosive growth
Michael Frazis describes his investment company’s strategy that involves a 30-40 year view, not panicking and diverting the approach during dips and rallies. Evaluating growth stocks involves identifying customer love for a product or service which acts a key indicator of explosive growth potential. This approach is utilized in picking winners in industries like the ‘buy now, pay later’ space. Frazis explains how vaccine development is a long process involving extensive trials and how the emergency approval of Moderna’s vaccine allowed the company to prove the mRNA concept, providing the company a significant boost.
TIMESTAMPS
0:00 - Intro and background
2:39 - Founding his company at 29 and investing strategy
11:38 - Evaluating polarizing stocks like Tesla
15:08 - Investing psychology
18:45 - Processing investment information
23:17 - Investing in industry creators
25:31 - Moderna and life sciences investments
31:43 - Dogecoin case study
35:30 - Growth stocks amid inflation
40 min
June 10, 2021 Episode 47: A disastrous decision from the FDA
Michael Frazis attempts to understand the FDA's decision to approve Biogen's aducanumab for Alzheimer's and the possible ramifications.
14 min